Doximity Stock Analysts Adjust Ratings and Targets

Analysts at Barclays, Morgan Stanley, and others have updated their views on the medical networking platform company.

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Doximity, Inc., the leading professional medical network for healthcare providers in the U.S., has seen several analysts adjust their ratings and price targets on the company's stock recently. The San Francisco-based company, founded in 2011, operates a HIPAA-compliant communication platform for physicians, nurse practitioners, and physician assistants to collaborate, share information, and stay up-to-date on clinical news.

Why it matters

As a newly public company, Doximity's stock performance and analyst coverage are closely watched by investors interested in the digital health technology sector. These rating and target changes provide insight into how Wall Street views the company's growth prospects and competitive positioning within the medical networking and communication space.

The details

On February 11, 2026, analysts at Barclays PLC lowered their price target on Doximity shares from $63 to $57. Meanwhile, Morgan Stanley maintained an 'Overweight' rating on the stock but reduced their target price from $68 to $65.

  • The analyst updates were issued on February 11, 2026.

The players

Doximity, Inc.

A San Francisco-based company that operates the leading professional medical network for healthcare providers in the United States. Doximity was founded in 2011 and went public in June 2021, trading on the NASDAQ under the ticker symbol 'DOCS'.

Barclays PLC

A multinational investment bank and financial services company headquartered in London, England.

Morgan Stanley

A global financial services firm and one of the largest investment banks in the world, headquartered in New York City.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

As a newly public company, Doximity's stock performance and analyst coverage will continue to be closely watched by investors interested in the digital health technology sector and the company's ability to maintain its leadership position in the medical networking and communication space.